Home / Companies / Cardiff Oncology, Inc. / 26 Jun 2025
Cardiff Oncology, Inc.: meeting of 26 Jun 2025
Votes reported on Form N-PX, item by item
147 Form N-PX filers reported votes at the Cardiff Oncology, Inc. meeting of 26 Jun 2025. Their records fall into 4 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
7 nominees; 99.5% of reported votes for; 2 filers withheld from or voted against at least one nominee.
630 vote records from 48 filers. 0 of the 47 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
203 vote records from 147 filers. 7 of the 143 filers that marked the item either way voted against management. 4 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
90 vote records from 48 filers. 0 of the 47 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
COMPENSATIONIssuer
COMPENSATION: management items
Management items in this category are shown together; filers word and number them differently.
90 vote records from 48 filers. 8 of the 47 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | For | For | For |
| BlackRock and iShares | For | For | For |
| Fidelity | For | For | For |
| State Street and SPDR | For | For | For |
| American Century | For | For | For |
| Invesco | No report | For | No report |
| Equitable | For | For | For |
| Charles Schwab | For | For | For |
| Nuveen and TIAA | For | For | For |
| ProShares and ProFunds | For | For | For |
| John Hancock and Manulife | For | For | For |
| Morgan Stanley, Eaton Vance and Calvert | For | For | For |
| J.P. Morgan | No report | For | No report |
| Goldman Sachs | For | For | For |
| PGIM and Prudential | No report | For | No report |
| Northern Trust and FlexShares | For | For | For |
| T. Rowe Price | For | For | For |
| Lincoln Financial | For | For | For |
| Voya | For | For | For |
| Nationwide | For | For | For |
| Victory Capital | For | For | For |
| Brighthouse Funds | For | For | For |
| Guggenheim and Rydex | For | For | For |
| Columbia Threadneedle | For | For | For |
| BNY Mellon | No report | For | No report |
| Principal | No report | For | No report |
| Pacific Life funds | For | For | For |
| Global X | For | For | For |
| AllianceBernstein | No report | Against * | No report |
| DWS | For | For | For |
| Neuberger Berman | No report | For | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Cardiff Oncology, Inc. meeting?
147 Form N-PX filers reported votes at the meeting of 26 Jun 2025. On say-on-pay, 7 of 143 voted against management (4.9%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Cardiff Oncology, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Cardiff Oncology, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Cardiff Oncology, Inc. with a meeting date within three days of 26 Jun 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.